摘要
目的探讨门冬胰岛素30联合盐酸二甲双胍缓释片和胰岛泵对2型糖尿病的疗效、安全性及性价比。方法 120例T2DM患者分为联合治疗组(联合组,60例)和泵组(CSII组,60例),两组的年龄、BMI、FC-P,FPG、2hC-P、2hPG、HbAlc等均无显著统计学差异(P>0.05)。结果联合组和泵组治疗均能有效控制血糖,FPG、2hPG,HbAlc均较治疗前显著下降(P<0.05);FC-P、2hC-P均较治疗前显著升高(P<0.05)。两组达到相同血糖水平所需的治疗时间以及低血糖发生率两组无显著统计学差异(P>0.05),但联合治疗组胰岛素用量显著少于CSII组(P<0.05)。结论门冬胰岛素30联合盐酸二甲双胍缓释片安全、有效控制血糖,且性价比高于胰岛素泵。
Objective To compare the efficacy and safety between insulin aspart 30 combined metformin hydrochloride sustained-release tablets with pre-meal short insulin and continuous subcutaneous insulin infusion （CSII） in type 2 diabetic patients. Methods 120 pa- tients with type 2 diabetes were divided into combined treatment group （combination group, 60 eases） and pump （CSII group, 60 cases） . There was no significant difference between the two groups in age, BMI, FC-P, FGP, 2 h C-P, 2 h PG, HbA1C （P 〉0.05）. Results After the treatment, combination group was as effective as CSII group in the parameters of the FpG, 2 h PG, FC-P, 2 h C-P （all P 〈0.05）. The average duration of treatment and hypoglycemia incidence showed no obvious difference between two groups （P 〉0.05）, but the insulin doses markedly decreased in combined group versus CSII group （P 〈0.05）. Conclusions Insulin aspart 30 combined metformin hydrochloride sustained-release tablets can control the hyperglycemia more effectively with reduced hypoglycemia risk, doses of insulin and and costs than insulin pump.
出处
《临床医学工程》
2010年第11期35-36,共2页
Clinical Medicine & Engineering
关键词
门冬胰岛素30
二甲双胍缓释片
胰岛素泵
糖尿病
Insulin aspart 30
Metformin hydrochloride sustained-release tablets
Continuous subcutaneous insulin infusion
Diabetes
